Soliqua 100/33 Solostar pens(Insulin Glargine / Lixisenatide)

Soliqua Solostar pens are called Suliqual in Europe.

Prescription Soliqua 100/33 is taken as an injection of the following 2 active ingredients:  insulin glargine and lixisenatide.  This medicine is used to control type 2 diabetes alongside of a good diet and exercise in adult patients. Soliqua 100/33 is a treatment option for people who take a long acting insulin or oral diabetic medicine but are not reaching their target blood sugar or A1C levels.  

Soliqua works five ways to help your body control diabetes.  Soliqua prevents sugar from building up in your blood.   It slows down your stomach from emptying too quickly.  It slows the liver process of releasing sugar.  It helps the pancreas to release more of its own insulin.  Soliqua also helps you muscle to store sugar that isn't required immediately so it can be used when required.

In studies, Soliqua lowered A1C levels almost twice as much as Lantus.

Soliqua Solostar pen is a once a day dosage, taken within an hour of your first daily meal.  Soliqua delivers control of blood sugar for 24 hours.

In 2019, when comparing Soliqua Solostar pen price to USA Soliqua coupon price, InsulinHub was found to offer a discount of approximately 40% in Soliqua savings.

Buy Soliqua Solostar pens from InsulinHub.com for the best Soliqua price.

Information about Soliqua 100/33 Solostar Pens (Insulin Glargine / Lixisenatide)

Soliqua 100/33 Solostar is a combination injectable medication containing insulin glargine and lixisenatide. Insulin glargine is a long-acting insulin that helps control blood sugar levels by promoting the uptake of glucose into cells. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps stimulate insulin secretion in response to meals and also slows gastric emptying to help control appetite and blood sugar levels. This combination medication is mainly used for the management of type 2 diabetes.

Product Highlights

• Soliqua 100/33 is indicated for adults with type 2 diabetes who need help in controlling blood sugar. It is used when oral medications and insulin alone are not enough to manage blood glucose levels.
• It is used in conjunction with diet and exercise to help improve blood sugar control in adults with type 2 diabetes. 
• This combination medication is used when basal insulin (like insulin glargine) and GLP-1 receptor agonist therapy (like lixisenatide) are both required.

Key Ingredient

• Insulin Glargine
• Lixisenatide

Key Benefits

• Combines both insulin glargine and lixisenatide in a single injection, simplifying diabetes management and reducing the number of injections needed.
• Offers dual action in controlling both fasting and post-meal blood sugar levels.
• Lixisenatide helps with weight management by reducing appetite and promoting satiety, which may be beneficial for individuals with type 2 diabetes who struggle with weight control.
• Insulin glargine provides steady, long-acting blood glucose control, reducing the need for frequent insulin injections.

Direction of Use

• Soliqua 100/33 should be injected subcutaneously (under the skin) once daily, typically in the evening, at the same time each day.
• Before using the pen, check the solution to ensure it is clear and colorless. Do not use if the solution is cloudy, discolored, or has particles in it. 
• The starting dose and adjustments should be determined by a healthcare provider based on the patient's individual blood glucose levels and insulin requirements.
• Clean the injection site with an alcohol swab, choose an area on the abdomen or thigh, and administer the dose according to the pen’s instructions.
• After each injection, dispose of the pen in a proper sharps container.

Safety Concerns

• Both insulin and GLP-1 receptor agonists can cause hypoglycemia. Patients should monitor their blood glucose levels regularly, especially if they are adjusting their dose or if they experience symptoms of low blood sugar (e.g., shaking, sweating, confusion).
• Lixisenatide may cause nausea, vomiting, diarrhea, or abdominal discomfort, particularly when starting treatment.
• There is a potential risk of pancreatitis (inflammation of the pancreas), so any symptoms of abdominal pain should be reported to a healthcare provider immediately.
• Caution should be exercised in patients with renal impairment, as both insulin and lixisenatide are excreted through the kidneys.
• While rare, some people may experience an allergic reaction to either of the components. Symptoms like rash, itching, or swelling should be monitored closely.

Avoid Soliqua 100/33 Solostar Pens (Insulin Glargine / Lixisenatide) If

• If you are allergic to insulin glargine, lixisenatide, or any other ingredients in Soliqua, you should avoid using this medication. 
• Soliqua is not suitable for the treatment of diabetic ketoacidosis, a serious complication of diabetes.
• Avoid if you have a history of severe gastrointestinal disease, such as gastroparesis (delayed gastric emptying), as lixisenatide can slow gastric emptying and worsen symptoms.
• Soliqua should be used with caution in patients with significant kidney problems, as both components are eliminated through the kidneys.
• The safety of Soliqua during pregnancy or breastfeeding has not been well established. Consult a healthcare provider before using Soliqua during pregnancy or while breastfeeding.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.